tiprankstipranks

Pacira announces new long-term follow-up data from Phase 1 trial on PCRX-201

Pacira (PCRX) BioSciences announced new long-term follow-up data from its Phase 1 clinical trial evaluating PCRX-201, a novel gene therapy candidate for osteoarthritis of the knee. Results show that a single intra-articular injection of PCRX-201 was well tolerated and produced sustained improvements in pain, stiffness, and function through 156 weeks in patients with moderate-to-severe osteoarthritis of the knee.

Don’t Miss TipRanks’ Half-Year Sale

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1